Roche Holding and Alnylam Pharmaceuticals said they decided to move experimental hypertension drug zilebesiran to a late-stage trial after results from mid-stage studies showed mixed results.

Cemdisiran helped control symptoms of generalized myasthenia gravis, but combination treatment with a Regeneron antibody didn ...

The agreement provides research funding for Replicate and up to $550M in payments to develop medicines for diseases including ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...

Source: Kidess GG, et al. Efficacy and safety of RNA interference therapeutics in patients with transthyretin amyloidosis cardiomyopathy. Presented at: American College of Cardiology Scientific ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was generally well tolerated among 14 patients with kidney disease. The ...

A recent eGastroenterology review by Professor Intissar Anan highlights major breakthroughs in transthyretin amyloidosis ...

Wall Street is looking for new ways to park cash in healthcare names, and l This asset class differs from traditional ...

Pfizer is taking a curtain call for Vyndaqel, the low-dose version of its blockbuster tafamidis franchise for the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM). | Pfizer is taking ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in ...

This Collection welcomes original research using RNA Interference, from genetic disorders to cancer, including methods and strategies on resolution and efficiency improvement.